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Background: Previous studies suggest that cancer-related interventions are valued by policy makers more favorably
than interventions for other medical conditions, but the views of practicing physicians have not yet been assessed
in Israel. Attitudes and judgments of practicing physicians may assist decision-makers in their deliberations on
coverage of new technologies. We conducted a national survey in Israel among oncologists and family physicians
to explore their views on access to care, coverage decisions and treatment recommendations for cancer and
congestive heart failure (CHF) patients.
Methods: We administered a web-based survey to 300 family physicians and 156 oncologists. The questionnaire
included 24 statements and physicians were asked to indicate their level of agreement with each statement on a
5-point Likert scale, ranging from “strongly agree” to “strongly disagree”. Where relevant, physicians were asked to
express their views on interventions for cancer and CHF respectively.
Results: Response rates were 39% for family physicians and 36% for oncologists. Participants expressed similar
views on cancer and CHF care and no significant differences were found between the two medical specialties.
More than 85% of physicians believe that inclusion of a treatment in the National List of Health Services (NLHS)
strongly affects their patients’ access to care. Approximately 80% suggest that more use of comparative-
effectiveness and cost-effectiveness analysis is needed in coverage decisions. The vast majority of respondents
(75%) suggest that assessment of value-for-money should be made by an independent (academic) institution or
the national committee responsible for recommending coverage decisions, Seventy percent believe that treatments
not included in the NLHS should be included in supplementary health insurance programs and only a small
minority of respondents (<30%) believe that cancer-related interventions should receive higher priority than
non-cancer interventions in coverage decisions.
Conclusions: Our findings suggest that both oncologists and family physicians value cancer and CHF interventions
equally. We could not find evidence for a “cancer premium” as implied from previous surveys and analysis of
coverage decisions in various countries.Background
Innovative interventions in medicine may improve patients’
survival and/or quality of life (QoL), but such improve-
ments frequently come at a substantial cost. Among health
interventions, the cost of cancer treatment has received* Correspondence: dangr@bgu.ac.il
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reproduction in any medium, provided the orincreased attention in the last decade mainly due to the
very high treatment costs associated with newly developed
chemotherapies and biological drugs [1-4]. The debate over
cancer drugs has focused not only on the costs of treat-
ments, but also on their relatively modest benefits, as many
new drugs, such as those for patients with metastatic
disease produce relatively small gains in life-expectancy or
QoL [1,2].
The access to, and affordability of, new expensive anti-
cancer drugs is of concern to patients, decision-makers
and the general public [5-12]. Since many cancer drugstral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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afford to pay for them themselves. Acknowledging the
unique circumstances of end of life care, and the high
cost of new cancer interventions which is beyond the
means of most patients, several jurisdictions and policy
makers have adopted special mechanisms for coverage
and reimbursement decisions on cancer drugs. Reim-
bursement agencies, like the National Institute for
Health and Care Excellence (NICE) in England, tend to
use more flexible criteria to value cancer drugs, even
when their cost-effectiveness ratio is higher than their
implicit or explicit threshold that determines “good
value for money” [5,12].
As of 1995, Israel has a National Health Insurance Sys-
tems that provides universal coverage for every citizen
or permanent resident who are free to choose from
among four competing non-profit health plans. The Na-
tional Health Insurance Law stipulates a National List of
Health Services (NLHS) which all residents are entitled
to from their health plans. Every year as part of the an-
nual budgeting process, the government determines the
additional budget that will be available to fund new tech-
nologies. The budget allocated is far from being suffi-
cient to keep up with the pressures of the growing
health care market, which makes priority setting and ra-
tioning inevitable. The recommendations on which new
technologies should be added to the NLHS are made by
a Public National Advisory Committee (PNAC). The
committee evaluates all proposed technologies consider-
ing clinical, economic, social and ethical aspects. Follow-
ing the governmental approval of the PNAC prioritized
list of new technologies, health plans are required by law
to supply the entire demand for these technologies
[13-18]. All cancer-related drugs listed in the NLHS are
not subject to patient copayment, whereas a copayment
is required for drugs for most other diseases. Individuals
that wish to be treated with medications that are not in
the NLHS formulary have to cover the costs, either
through out-of-pocket payments or via private health
insurance.
In general, drugs and other interventions that are not
included in the NLHS may be included in supplemen-
tary insurance programs offered by health plans to their
members, or by for-profit commercial health insurance
programs. However, as of 2007, the health plans’ supple-
mentary insurance programs are prohibited from offer-
ing coverage for cancer medications and interventions
[19]. The reason for this prohibition was a concern that
several drugs not included in the NLHS will be available
only to those that purchased voluntary health insurance,
thus creating two ‘classes’ of public healthcare.
Israel is considered an early adopter of many technologies,
granting public funding prior to their coverage in other
healthcare systems. Among disease types, the proportion ofthe budget allocated to fund new drugs for treating life-
threatening oncology diseases is substantial and exceeds
other therapeutic areas [20]. This might imply that decision-
makers in Israel give a higher priority to interventions aimed
at treating cancer patients rather than other life-threatening
medical conditions. Although the coverage decision
process in Israel does not explicitly use results from cost-
effectiveness analysis [17,18], studies have suggested that in
many cases, the recommended technologies for inclusion in
the NLHS are those with favorable cost-effectiveness results
[21]. Nevertheless, the maximum societal willingness to pay
for a life year or a quality adjusted life-year (QALY) gained
has not yet been determined by policy makers in Israel.
Advanced congestive heart failure (CHF) is similar to
metastatic cancer, in that both are life-threatening med-
ical condition. Although drug therapy for CHF may be
substantially cheaper than cancer drugs, the cost per pa-
tient of several implantable devices such as left ventricu-
lar assist devices (LVAD) and cardiac resynchronization
therapy (CRT) devices may exceed $US100,000 and their
cost-effectiveness remains uncertain [22,23].
Oncologists and family physicians attitudes towards the
cost of cancer care
Practicing oncologists are frequently on the front line of
the controversy over expensive cancer treatments,
having to decide whether to offer their patients new and
expensive treatments, sometimes not included in the
NLHS. Very often, these decisions are complicated by
the financial burden such treatments place on patients
and their families as their costs might be beyond many
people’s means [24,25]. For example, two drugs included
in the 2013 update of the NLHS (Vandetanib for medul-
lar thyroid cancer and Vismodegib for basal cell carcin-
oma) cost more than $US100,000 for an average patient
treatment protocol. Although oncologists play a funda-
mental role in treatment decisions, little is known about
Israeli oncologists’ attitudes towards cancer costs, their
beliefs about whether costs influence their prescribing of
non-reimbursed drugs, and their comfort and readiness to
make such decisions. We also know very little about oncol-
ogists’ beliefs regarding the use of cost-effectiveness infor-
mation or their views on policies regarding access and
reimbursement. Only recently, several studies from the U.S.
and Canada have examined American oncologists’ attitudes
on those aspects [26-29]. Similar to oncologists, family phy-
sicians may also be involved in their patients’ decisions
whether to opt for care of very costly treatments, some-
times with only marginal benefits. As they are exposed to a
wide variety of medical conditions and perhaps because of
other factors, family physicians may have different views on
health interventions than those possessed by oncologists.
Attitudes and judgments of practicing physicians may assist
decision-makers in their deliberations on coverage of new
Greenberg et al. Israel Journal of Health Policy Research 2013, 2:44 Page 3 of 10
http://www.ijhpr.org/content/2/1/44technologies and whether treatments for cancer, for ex-
ample, should be assessed using different criteria and
receive a higher priority, as compared with other interven-
tions. We therefore conducted a national survey in Israel
among oncologists and family physicians to explore their
views on access to care, coverage decisions and treatment
recommendations for cancer and congestive heart failure.Methods
Survey development
We developed a questionnaire to assess oncologists’
and family physicians’ views on various aspects of
cancer and congestive heart failure treatment costs,
cost-effectiveness (value for money), patients’ access
to care as well as views on health policies relating to
coverage and reimbursement decisions for these treat-
ments. To allow comparison with findings from other
healthcare systems [26-29], the questionnaire was par-
tially based on a survey of oncologists in the United
States and Canada. Several questions included in the
original surveys were not relevant to the practice in
Israel and were therefore omitted. We added ques-
tions specifically relating to the decision-making
process regarding coverage of new technologies as
well as inclusion of interventions not granted public
funding in private health insurance programs (supple-
mental health insurance offered by health plans, or
private insurance offered by commercial health insur-
ance companies). Physicians were asked to indicate
their level of agreement with each statement on a 5-
point Likert scale, ranging from “strongly agree” to
“strongly disagree”.
Where relevant, respondents were asked to express
their views on both interventions for cancer and
congestive heart failure. For example: all physicians
were asked to comment on the following statements:
“Every patient should have access to effective cancer
treatments regardless of their cost.”
“Every patient should have access to effective
congestive heart failure treatments regardless of their
cost.”
As oncologists treat only cancer patients they were
not asked to express their views on questions relat-
ing directly to treatment of CHF patients (e.g.,
”whether the treatment for congestive heart failure is
included in the National List of Health Services in
Israel highly influences my patients’ access to this
treatment”).The questionnaire administered to oncologists in-
cluded 22 statements, and family physicians were asked
to comment on 24 statements.
We also asked respondents what they thought a
reasonable definition of “good value for money” or
cost-effectiveness per life year gained is? (Response
categories were $0-25,000, $25,001-50,000, $50,001-
75,000, $75,001-100,000, $100,001-125,000, $125,001-
150,000, $150,001-175,000, 175,001-200,000 and more
than $200,000, and reflect the maximum willingness
to pay or threshold per life-year). We also questioned
them about who they think should determine whether
an intervention provides good value for money. Pos-
sible answers included the Public National Advisory
Committee (responsible for recommending which
technologies should be included in the NLHS), an in-
dependent academic or research institution, the Min-
istry of Health or the Ministry of Finance, the health
plans, private health insurance companies, or the pa-
tients themselves. Finally, we collected physicians’
demographic data and information on medical train-
ing and practice.
Study population and survey administration
We sent the questionnaire to 156 board-certified oncolo-
gists with a valid email address and to a randomly selected
sample of 300 board-certified family physicians received
from the Israel Association of Family Physicians. The list of
oncologists was compiled based on the directory of the
Israeli Society of Clinical Oncology and Radiotherapy
(ISCORT) and from the list of physicians practicing in
general medical centers and in the Israeli four health plans.
The survey questionnaire was developed and dis-
tributed using the Qualtrics Online Survey Software
(Qualtrics Labs, Inc. Provo, Utah, USA). Subsequent
to pilot-testing for clarity and technical properties,
participants received an e-mail invitation to complete
the web-based questionnaire and a link to the ques-
tionnaire. To avoid ordering bias, each participant
received and answered the above-mentioned questions
in a random order. Differences in oncologists’ and
family physicians’ views and training characteristics were
assessed using chi-square tests. All analyses were performed
using PASW Statistics 18. P values < 0.01 were considered
statistically significant for all comparisons.
The study was approved by the ethics committee of
the Faculty of Health Sciences of Ben-Gurion University
of the Negev.
Results
We received responses from 52 oncologists and 116
family physicians for overall response rates of 36%
and 39% respectively. Ten out of the 156 oncologists
did not practice medicine in Israel and were therefore







Age (Mean ± SD) 54.6 (10.8) 50.1 (9.2) 0.006
Female 50.0% 51.7%
Male 50.0% 48.3% NS
Years (Mean ± SD) of work
experience in Medicine
28.6 (11.2) 23.1 (9.5) 0.001
Medical School
Israel 48% 57% NS
Western Europe andAmerica 13% 16%
Eastern Europe 27% 24%
Other 12% 3%












Salaried and self-employed 27%
Other 3%
Main practice setting
Health plan (HMO) 6%
Other 2%
Main practice setting
Public hospital 86% 2%
Health plan (HMO) 91%
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demographics and medical training characteristics
are presented in Table 1. Approximately 50% of
respondents were male; oncologists were older, had
substantially longer experience in medical practice
and approximately 40% had a fellowship training in
the United States. The main practice setting of the
vast majority of oncologists (87%) was in public
hospitals, while almost all primary care physicians
practiced medicine in one of the four health plans.
Physicians’ views on coverage and reimbursement of new
interventions for cancer and congestive heart failure
Oncologists’ and family physicians’ views on the cover-
age and reimbursement decisions of new technologies
and the related health policies are summarized in Table 2.
Overall, oncologists and family physicians expressed
similar views on these topics.
Most respondents did not think that cancer and CHF
interventions should receive higher priority in the
PNAC’s deliberations. The majority of physicians believe
that data on the cost-effectiveness of new interventions
should be used to support whether these interventions
should be included in the NLHS. Nevertheless, only less
than half of respondents believe that only treatments
that provide “good value for money”, i.e. are cost-
effective, should be included in this list. The median
range of cost-effectiveness threshold thought to reflect
good value for money for cancer interventions ($US/life
year gained) was lower for family physicians (25,000-
$50,000), compared with oncologists (50,000-$75,000).
About half of respondents supported the statement
that only interventions that provide substantial survival
gains should be listed. A similar proportion of physicians
believed that only interventions that offered improve-
ment in patients’ quality of life (even with no survival
gain) should be included in the NLHS. In terms of who
they believe should determine whether an intervention
provides good value for money, approximately half of
Israeli physicians (regardless of type of medical specialty)
favored having an academic or research institution,
followed by the PNAC (30%), and the Ministries of
Health and Finance (15%). Only very few suggested that
these decisions should be made by health plans, the
physicians or the patients themselves.
Physicians’ attitudes regarding access to care and
treatment recommendations
Physicians’ attitudes regarding access to cancer and CHF
interventions and influences on recommended treatments
are summarized in Table 3. Overall, oncologists and family
physicians expressed similar views and concerns about ac-
cess to care regardless of type of disease. Almost all physi-
cians suggested that inclusion of an intervention in theNLHS in Israel highly influences their patients’ access to
care. However, a lower proportion of oncologists and family
physicians (54-77%) indicated that a drug listing in the
Table 2 Views on coverage and reimbursement decisions





New cancer drugs should receive a higher priority compared with treatment for other diseases in
the deliberations of the Public National Advisory Committee in Israel
27% 30% NS
New treatments for congestive heart failure should receive a higher priority compared with
treatment for other diseases in the deliberations of the Public National Advisory Committee in Israel
17% 22% NS
Only effective cancer treatments that provide “good value for money” should be included in the
National List of Health Services
48% 42% NS
Only effective treatments for congestive heart failure that provide “good value for money” should be
included in the National List of Health Services
42% 42% NS
Using data on the cost-effectiveness of cancer drugs to support decisions whether to include these
drugs in the National List of Health Services should be encouraged
73% 77% NS
Using data on the cost-effectiveness of congestive heart failure drugs to support decisions whether
to include these drugs in the National List of Health Services should be encouraged
77% 81% NS
Only cancer drugs that provide substantial survival gains in comparison with the current treatment
should be added to the National List of Health Services
62% 52% NS
Only treatments for congestive heart failure that provide substantial survival gains in comparison
with the current treatment should be added to the National List of Health Services
56% 52% NS
Only cancer drugs that provide substantial improvements in patients’ quality of life in comparison
with the current treatment (and no survival gains) should be added to the National List of Health
Services
53% 50% NS
Only treatments for congestive heart failure that provide substantial improvements in patients’
quality of life in comparison with the current treatment (and no survival gains) should be added to
the National List of Health Services
50% 54% NS
Over the next five years, the high cost of new cancer drugs will cause the Public National Advisory
Committee to recommend the funding of only very few new treatments
62% 64% NS
Who should determine whether a new intervention provided good value for money?
Independent academic or research institution 44% 47%
The Public National Advisory Committee 29% 30%
Ministry of Health or Ministry of Finance 17% 14%
Health plans 2% 3%
The physician 6% 1%
The patient 2% 5%
Private health insurance companies 0% 0%
Other 1%
What do you think is a reasonable definition of “good value for money” or cost-effectiveness per
life-year gained ($ per life-year)
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tions. Only very few physicians (10% of respondents)
believe that patient co-payment for cancer drugs
should be charged, even if the drug is included in the
NLHS. More than two-thirds of physicians indicated
that a treatment not included in the NLHS should becovered by either supplementary or by commercial
health insurance programs.
A higher proportion of oncologists (77% of oncologists
vs. 54% of family physicians; p = 0.005) suggested that the
inclusion of a cancer drug in the NLHS will influence their
treatment recommendations. Relatively few respondents
Table 3 Attitudes regarding access to care and treatment recommendations





Whether a cancer drug is included in the National List of Health Services influences my decision
regarding which cancer treatment to recommend to my patients
77% 54% 0.005
Whether an intervention for congestive heart failure is included in the National List of Health
Services influences my decision regarding which treatment to recommend to my patients
65%
Whether a cancer drug is included in the National List of Health Services highly influences my
patients’ access to treatment
92% 84% NS
Whether a treatment for congestive heart failure is included in the National List of Health Services
highly influences my patients’ access to treatment
86%
Every patient in Israel should have access to effective cancer treatments regardless of their cost 65% 55% NS
Every patient in Israel should have access to effective treatments for congestive heart failure
regardless of their cost
73% 59% NS
Every effective cancer drug that is not included in the National List of Health Services should be
included in the supplementary insurance offered by health plans
65% 76% NS
Every effective treatment for congestive heart failure that is not included in the National List of
Health Services should be included in the supplementary insurance offered by health plans
65% 78% NS
Every effective cancer drug that is not included in the National List of Health Services should be
included in commercial health insurance plans offered by private health insurance companies
75% 72% NS
Co-payment on cancer drugs is needed even if the drugs are included in the National List of Health
Services
10% 10% NS
More research on comparative analysis of cancer drugs is needed 83% 85% NS
Data on the cost-effectiveness of new cancer drugs may have an impact on which treatment proto-
col to recommend to my patients
52% 64% NS
The notion that my patients will have to pay for a cancer drug “out of pocket” will influence my
decision regarding which treatment protocol to recommend to my patients
79% 56% NS
How often do you discuss the costs of cancer drugs with your patients?
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that they always or frequently discuss the costs of new can-
cer drugs with their patients, and only 18% of family physi-
cians discuss with their patients the costs of CHF care.
Discussion
Our study describes oncologists’ and family physicians’
attitudes toward the funding of and access to new inter-
ventions for cancer and congestive heart failure in the
Israeli publicly funded health insurance system. Thisstudy adds to our previous analysis that examined how phy-
sicians value life-prolongation versus QOL-enhancing out-
comes attributable to cancer and CHF interventions [30].
We were specifically interested in whether physicians
believe that cancer interventions should be given “spe-
cial care” as suggested in previous studies and analysis of
coverage decisions in other jurisdictions. In addition to
exploring the attitudes of oncologists, which has been
studied in previous surveys in the U.S. and Canada, we
also surveyed family physicians. As family physicians are
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and medical conditions, they may have more balanced
views as compared with oncologists, who only care for
cancer patients.
Coverage and reimbursement decisions
Approximately half of the physicians favor an independ-
ent academic or research institution as the organization
that should determine whether an intervention provides
good value for money. The PNAC, currently responsible
for recommending which technologies should be added
to the NLHS, is less favored in completing this task.
These views should be considered if cost-effectiveness
analyses will become mandatory in making coverage
decisions in Israel, as is already happening in several
countries including the U.K, Australia, and Canada [5].
The majority of respondents in our survey felt that
interventions not included in the NLHS in Israel should
be covered under alternative complementary insurance
plans. As mentioned earlier, although approximately 75%
of the Israeli population is also covered by supplemen-
tary voluntary health insurance, the Ministry of Health
banned the coverage of cancer drugs in these programs,
although some plans already offered this benefit for their
members for a relatively small premium. In return, the
Ministry of Finance signed a three year agreement to
allocate substantial funds for adding new technologies to
the NLHS. The restrictions on supplementary health
insurance plans were mainly due to equity concerns that
created a situation where only patients with voluntary
health insurance will have access to some of the import-
ant cancer medications. This decision has created major
discussions and a debate among health plans, the Minis-
try of Health and patient advocate organizations. As this
debate is still ongoing, the attitudes of the physicians in
our study may serve as another argument for those
objecting to this policy.
Comparative effectiveness and cost-effectiveness
A large majority of physicians in our study indicated that
more data on cost-effectiveness should be used to
support coverage decisions on new cancer and CHF
interventions considered for inclusion in the NLHS. A
smaller, though still sizeable proportion of physicians
(approximately 60%) suggested that data on the cost-
effectiveness of new cancer drugs may influence their
decisions on which treatment protocol to recommend to
their patients. These results are somewhat interesting, as
results from cost-effectiveness analyses are not currently
used to inform coverage decisions in Israel. Moreover,
practicing physicians are not regularly exposed to cost-
effectiveness information and are not prepared to factor
cost-effectiveness results into their treatment decisions.
Our results are similar to attitudes revealed by Canadianand U.S oncologists (Table 4). Although cost-effectiveness
analysis is used in Canada for making funding decisions on
cancer drugs, U.S. policy makers are reluctant to use results
from economic analyses, which may be viewed as an at-
tempt to explicitly ration health care [5]. As suggested pre-
viously [27], one possible explanation for these unexpected
findings is that physicians are beginning to acknowledge
the unavoidable use of “value for money” considerations,
given the relatively low benefits and very high costs associ-
ated with new cancer drugs.
In terms of what cost-effectiveness thresholds were felt
to represent “good value for money,” Israeli family physi-
cians endorsed lower thresholds than oncologists. More-
over, both values were lower than cost-effectiveness
thresholds endorsed by U.S. and Canadian oncologists;
while in these countries approximately one third of phy-
sicians endorsed a value higher than $100,000 per life-
year, only 11% of physicians in Israel suggested that this
value is appropriate [30].
Research on comparative effectiveness has received in
recent years an increasing priority in many Western
countries; however, when cancer drugs are considered,
informative head-to-head clinical trials which are most
relevant to decision-makers and practicing physicians
are seldom performed. Therefore, it is not surprising
that, similar to attitudes expressed by oncologists in
Canada and in the U.S., both oncologists and family phy-
sicians in Israel believe that more research on compara-
tive effectiveness of cancer drugs is needed. As opposed
to cost-effectiveness analyses that must be adapted indi-
vidually to each healthcare system, data on comparative
effectiveness can be shared and used across countries
and jurisdictions.
Access to care
A large majority of Israeli physicians indicated that out-
of-pocket payment for cancer drugs will influence their
decisions regarding which treatment protocol to recom-
mend to their patients. In this regard, Israeli physicians
share similar views with their U.S. and Canadian coun-
terparts. Of note, the NLHS in Israel offers a generous
coverage of cancer drugs and listed drugs are not subject
to patient co-payment. Although almost every FDA
approved cancer drug in the U.S. is covered by health
insurance programs, copayments for these drugs fre-
quently pose a very high financial burden on patients
and their families. As some provinces in Canada do not
cover some of the new and expensive cancer drugs,
patients have been recently facing higher co-payment
costs. Therefore, it seems that Israeli physicians were re-
ferring to those interventions not currently covered
under the National Health Insurance.
It is also not surprising that Israeli physicians do not
discuss the cost and the proportion of physicians that
Table 4 Oncologists’ views: comparisons across countries





Only effective cancer treatments that provide “good value for money” should be included in the National List of
Health Services*
44% 58% 75%
Every patient in Israel should have access to effective cancer treatments regardless of their cost 58% 67% 52%
Using data on the cost-effectiveness of cancer drugs to support decisions whether to include these drugs in the Na-
tional List of Health Services should be encouraged*
76% 80% 69%
Co-payment on cancer drugs is needed even if the drugs are included in the National List of Health Services 10% 29% 41%
More research on comparative analysis of cancer drugs is needed 84% 79% 85%
Over the next five years, the high cost of new cancer drugs will cause the Public National Advisory Committee to
recommend the funding of only very few new treatments*
63% 73% NA
The notion that my patients will have to pay for a cancer drug “out of pocket” will influence my decision regarding
which treatment protocol to recommend to my patients
63% 84% 80%
How often do you discuss the costs of cancer drugs with your patients?
Always 2% 7% 7%
Frequently 15% 36% 41%
Occasionally 41% 37% 41%
Rarely 32% 17% 0%
Never 11% 3% 1%
What do you think is a reasonable definition of “good value for money” or cost-effectiveness per life-year gained ($
per life-year)
0–50,000 57% 21% 12%
50,001-100,000 32% 49% 56%
>100,000 11% 30% 33%
Data for Israel is a summary of responses of all physicians (oncologists and family physicians). Data for the U.S. and Canada are summary of oncologists’ attitudes.
* Statements presented to physicians in Israel were slightly different than those presented to physicians in the U.S. and Canada, and were modified to reflect the
practice and health insurance structure in Israel and the access to care granted through a National List of Health Services (NLHS) in Israel.
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their patients is substantially lower than reported by
their U.S. and Canadian colleagues, where co-payment
on cancer drugs is prevalent (Table 4). Moreover, the
proportion of oncologists reporting that they discuss the
cost of treatment with their patients is substantially
higher as compared with family physicians. This is not
surprising as the final treatment recommendations for
cancer patients, as well as their clinical and financial
consequences, are made by oncologists and not by fam-
ily physicians. Likewise, treatment recommendations for
CHF patients are most likely made by cardiologists.
Limitations
Our study has several limitations. First, the initial
sample size was somewhat small compared with pre-
vious surveys of this kind conducted in the U.S. and
Canada [26-29], partially because the number of
board-certified oncologists is small. The modest re-
sponse rate, despite our major efforts to contact and
encourage physicians to respond to the survey, might
mean that our results may be subject to responsebias. As we did not have information on the charac-
teristics of physicians in our sample frame, we were
unable to compare characteristics of respondents and
non-respondents and can not assure that those that
answered our survey adequately represent physicians
in term of demographic and practice characteristics.
Indeed, a comparison of our physician sample and
the characteristics of board-certified physician popula-
tion published by the Israel Ministry of Health indi-
cates that in the case both oncologists and family
physicians the ratio of males to females is roughly
50/50, similar to the split of physicians in Israel. For
family physicians, the age distribution of the sample
is also similar to that of the population. However,
in the case of oncologists, the sample appears to
over-represent oncologists aged 65+, while under-
representing those under 45. Finally, due to the rela-
tively small sample size, we were unable to assess
whether physician attitudes are influenced by their
characteristics (e.g., age, gender, practice experience),
as well as previous training in health policy and man-
agement and managerial experience.
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In general, oncologists and family physicians have simi-
lar attitudes on coverage and reimbursement decisions,
as well as on treatment recommendations and access to
innovative care. Although some minor differences in
attitudes between these physician groups do exist, most
of these differences can be considered as gradations of
opinions rather than completely different outlooks.
Moreover, physicians expressed similar views on cancer
and CHF care. This implies that, at least in the opinion
of practicing physicians, cancer interventions should not
be given special care (i.e., apart from their relative cost
and effectiveness) in coverage decisions, as is implicitly
suggested by coverage decisions in Israel. A higher prior-
ity granted to cancer drugs in resource allocation deci-
sions may lead to misallocation of resources. A recent
analysis scrutinizing the NICE “end-of-life premium” in
England, where special additional weight is given to
health gains from life-extending end-of-life treatments
(most frequently end-stage cancer patients), concluded
that this policy may be inconsistent with any attempt to
assess the value for money of public expenditure on
medical technologies [12]. Whether cancer interventions
should be granted a higher priority in the prioritization
process or not should be also assessed among a sample
of the adult population in Israel.
We believe that the views of practicing physicians in
Israel should be given some weight in national coverage
decisions, and specifically in the process of updating the
NLHS. Currently, most professional medical societies, in-
cluding The Israeli Society of Clinical Oncology and Radio-
therapy (ISCORT) are approached and asked to prioritize
the technologies proposed for inclusion in the NLHS in
their relevant medical field. This ranking is given some
weight in the deliberations of the PNAC and medical ex-
perts are consulted regarding specific technologies. We be-
lieve that family physicians that may have a broader
perspective on various disease areas should also be
approached and present their views to the committee, not
only on specific technologies prescribed routinely by family
physicians.
Physicians in Israel, as for their counterparts in the U.S.
and Canada, believe that over the next years, due to the
increasing costs of innovative cancer drugs, the coverage of
only few cancer treatments will be possible. Coverage of
new interventions will be also influenced by the recent
austere conditions in many countries and the associated
budget cuts. Under these conditions, choosing among those
interventions with the highest efficacy and more specifically
those that provide the best value for money becomes much
more relevant. As Israel is considered an early adopter of
new technologies, coverage decisions are currently made
while supporting information on both the effectiveness and
cost-effectiveness of new interventions is limited.However, as suggested by physicians in Israel, Canada,
and the U.S., more use of comparative effectiveness and
cost-effectiveness studies would be beneficial. These and
other considerations may be combined into a multi-
criteria decision analysis approach as has been recently
suggested [18].
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